Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-03-04

Clinical Trial Update: A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH [Phase 2]

View source ↗

Summary

A Phase II trial evaluating GV1001 for efficacy and safety in benign prostatic hyperplasia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GV1001

Snippet

Sponsor: GemVax & Kael | Conditions: Benign Prostatic Hyperplasia (BPH) | Phase 2 | Status: COMPLETED